Please assess the completion status of the following clinical trial:

Trial Title: This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Chronic hepatitis C, diagnosed by positive anti-hepatitis C virus(HCV) antibodies and detected HCV ribonucleic acid(RNA) at screening in addition to:~  1. positive anti-HCV antibodies or detected HCV RNA at least 6 months prior to screening; or,~ 2. liver biopsy consistent with chronic HCV infection.~* HCV infection of genotype 1 confirmed by genotypic testing at screening~* Therapy-naïve to interferon, pegylated interferon, ribavirin or any antiviral / immunomodulatory drug for acute or chronic HCV infection.~* Plasma HCV RNA = 100,000 IU/mL at screening~Exclusion criteria:~* Hepatitis C infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening~* Human immunodeficiency virus (HIV) co-infection~* Decompensated liver disease, or history of decompensated liver disease~* Body weight \< 40 or \> 125 kg at screening~* Hemoglobin \<12.0g/dL for women and \<13.0g/dL for men at screening~* White blood cell count \<3000 cells/mm3 at screening~* Absolute neutrophil count \< 1,500 cells/mm3 at screening~* Platelet count \< 90,000 /mm3 at screening~* Serum creatinine \> 1.5xUpper Limit of Normal range(ULN) or creatinine clearance =50 mL/min at screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BI 207127 NA, BI 201335 NA(high dose), R (Type: EXPERIMENTAL): Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
- BI 207127 NA,BI 201335 NA(low dose),RBV (Type: EXPERIMENTAL): Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks

Based on this trial design, predict the completion outcome and termination type (if applicable).